Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Invested Capital: 2010-2025

Historic Invested Capital for Catalyst Pharmaceuticals (CPRX) over the last 13 years, with Sep 2025 value amounting to $920.2 million.

  • Catalyst Pharmaceuticals' Invested Capital rose 39.23% to $920.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $920.2 million, marking a year-over-year increase of 39.23%. This contributed to the annual value of $727.6 million for FY2024, which is 87.59% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Invested Capital of $920.2 million as of Q3 2025, which was up 7.50% from $856.0 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Invested Capital ranged from a high of $920.2 million in Q3 2025 and a low of $178.7 million during Q1 2021.
  • Moreover, its 3-year median value for Invested Capital was $608.7 million (2024), whereas its average is $597.7 million.
  • Data for Catalyst Pharmaceuticals' Invested Capital shows a peak YoY soared of 89.63% (in 2024) over the last 5 years.
  • Quarterly analysis of 5 years shows Catalyst Pharmaceuticals' Invested Capital stood at $206.8 million in 2021, then skyrocketed by 45.25% to $300.4 million in 2022, then increased by 29.11% to $387.9 million in 2023, then spiked by 87.59% to $727.6 million in 2024, then surged by 39.23% to $920.2 million in 2025.
  • Its Invested Capital was $920.2 million in Q3 2025, compared to $856.0 million in Q2 2025 and $794.3 million in Q1 2025.